Abstract
Introduction Indian pharmaceutical industry being one of the largest pharmaceutical markets in the world has a large number of branded formulations and generic brands of the same drug with a large difference in their selling price. The study was planned to find out variation in cost of oral hypolipidemic drugs
Methods Information was sourced from NETMED MOBILE APP. The drug formulation being manufactured by only one company or being manufactured by different companies; however, in different strengths would be excluded. Difference in the maximum and minimum price of the same drug formulation manufactured by different pharmaceutical companies and percentage variation in price would be calculated.
Results The cost ratio’s and cost variation of all drugs including monocomponent drugs and fixed drug combinations (FDC’s) is above 100%. The maximum being Atorvastatin 20 mg in monocomponent drugs and Atorvastatin 10 mg + Fenofibrate 160 mg in FDC’S.
Conclusion Thus, this study highlights that there is a significant price difference among the hypolipidemic drugs manufactured by different companies. Hence stringent measures should be brought into implementation by the government and concerned agencies for uniformity in drug pricing.
Keywords
Full Text:
References
Sundaram VM. Pharma industry in India. Drug News Perspect. 2008;21(1):59-63.
Shankar PR, Subish P, Mishra P, Lalit M. Ambiguous pricing of Nepalese medicines. J Inst Med. 2006;28(3):35-8.
Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012;33(13):1635-701.
Pais P, Pogue J, Gerstein H, Zachariah E, Savitha D, Jayprakash S, et al. Risk factors for acute myocardial infarction in Indians: a case-control study. Lancet. 1996;348(9024):358-63.
Chitra U, Reddy NK, Balakrishna N. Role of lifestyle variables on the lipid profile of selected South Indian subjects. Indian Heart J. 2012;64(1):28-34.
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet. 1994;344(8934):1383-9.
Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335(14):1001-9.
Byington RP, Jukema JW, Salonen JT, Pitt B, Bruschke AV, Hoen H, et al. Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. Circulation. 1995;92(9):2419-25.
Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333(20):1301-7.
Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16(2):434-44.
Chen Z, Peto R, Collins R, MacMahon S, Lu J, Li W. Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. BMJ. 1991; 303(6797):276-82.
Anderson TJ, Grégoire J, Hegele RA, Couture P, Mancini GB, McPherson R, et al. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol. 2013;29(2):151-67.
Keaney JF Jr, Curfman GD, Jarcho JA. A pragmatic view of the new cholesterol treatment guidelines. N Engl J Med. 2014;370(3)275-8.
National Pharmaceutical Pricing Authority, Government of India. Available at http://www.nppaindia.nic.in/DPCO2013. pdf. Accessed on 04 Nov 2014.
National Pharmaceutical Pricing Authority, Government of India, Current Price list. Available at http:// www.nppaindia. nic.in/ ceiling/ press 28 april14/so1156e-28-4.14.html. Accessed 04 Nov 2014.
National List of Essential Medicines of India. Available at http://www.mohfw.nic.in/Write Read Data/ l892s/7364497513 National %20List %20of%20 Essential%20Medicine, %202011.pdf. Accessed 04 Nov 2014.
Das SC, Mandal M, Mandal SC. A critical study on availability and price variation between different brands: impact on access to medicines. Indian J Pharm Sci. 2007;69(1):160-3
Muir KW, Lee PP. Glaucoma Medication Adherence: Room for Improvement in Both Performance and Measurement. Arch Ophthalmol. 2011 Feb; 129(2):243-5.
Brown MT, Bussell JK. Medication Adherence: WHO Cares? Mayo Clin Proc. 2011 Apr;86(4):304-14.
Chandrappa S, Rajarathna K. Cost variation analysis of various brands of topical eye preparations currently available in Indian pharmaceutical market. Int J Basic Clin Pharmacol 2018;7(12):2364-7.
Allisabanavar SA, Narayana Reddy S. Cost variation analysis of various brands of anti-epileptic drugs currently available in Indian pharmaceutical market. International Journal of Basic & Clinical Pharmacology. 2017;6(7):1666-69.
Refbacks
- There are currently no refbacks.
Copyright (c) 2019 Journal of Pharmaceutical and Biomedical Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.